Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

10.04EUR
11:35am EDT
Change (% chg)

€-0.20 (-1.95%)
Prev Close
€10.24
Open
€10.23
Day's High
€10.23
Day's Low
€10.02
Volume
33,932
Avg. Vol
195,987
52-wk High
€18.07
52-wk Low
€9.09

Select another date:

Wed, Jul 12 2017

BRIEF-AB Science announces issuance of a new european patent

* REG-AB SCIENCE ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING THE USE OF MASITINIB IN PANCREATIC CANCER PATIENTS

BRIEF-AB Science presents supportive data from its phase 3 study in severe systemic mastocytosis

* PRESENTS SUPPORTIVE DATA FROM ITS PHASE 3 STUDY IN SEVERE SYSTEMIC MASTOCYTOSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-EU Medicines Agency recommends against approval of AB Science mastocytosis drug Masitinib

* EU Medicines Agency recommends approval of Valeant Pharmaceuticals Inc psoriasis drug Brodalumab

BRIEF-AB Science presents Phase 3 data for Masitinib in amyotrophic lateral sclerosis (ALS)

* PRESENTS PHASE 3 DATA FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)

BRIEF-Ab Science: CHMP adoptes negative opinion for masitinib in indolent systemic mastocytosis

* REG-AB SCIENCE ANNOUNCES THAT CHMP HAS ADOPTED A NEGATIVE OPINION FOR MASITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS, PRIMARILY DUE TO GCP INSPECTION FINDINGS

BRIEF-Trading resumption on shares of AB Science

* Announced today that trading on ordinary shares issued by AB Science will resume on Euronext Paris as of May 16, 2017 at 0900 CET Further company coverage: (Gdynia Newsroom)

BRIEF-AB Science - ANSM requested temporary suspension of masitinib studies

* Notification from ANSM requesting temporary suspension of ongoing masitinib studies until compliance is confirmed by an external audit

BRIEF-AB Science FY net loss widens to 27.7 million euros

* Reported on Monday FY net revenues of 1.5 million euros ($1.64 million) versus 2.3 million euros a year ago

BRIEF-AB Science issues 1.2 mln new ordinary shares - Euronext

* AB Science SA issues 1,241,831 new ordinary shares, which will be listed on Euronext Paris market as of April 4, 2017 Further company coverage: (Gdynia Newsroom)

BRIEF-Ab Science announces that masitinib passed its non-futility test at 2 years

* Announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years

Select another date: